Mackenzie Financial
BIO icon

Mackenzie Financial’s Bio-Rad Laboratories Class A BIO Stock Holding History

Mackenzie Financial’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,402
Closed -$338K – 1712
2025
Q2 		$338K Sell
1,402
-245
-15% -$57.9K ﹤0.01% 1354
2025
Q1 		$401K Buy
1,647
+1,018
+162% +$306K ﹤0.01% 1268
2024
Q4 		$207K Buy
+629
New +$214K ﹤0.01% 1553
2024
Q3 		– Sell
-1,054
Closed -$288K – 1587
2024
Q2 		$288K Buy
1,054
+322
+44% +$93.7K ﹤0.01% 1181
2024
Q1 		$253K Sell
732
-644
-47% -$212K ﹤0.01% 1253
2023
Q4 		$444K Buy
1,376
+444
+48% +$139K ﹤0.01% 1028
2023
Q3 		$327K Sell
932
-1,238
-57% -$478K ﹤0.01% 1111
2023
Q2 		$819K Buy
2,170
+342
+19% +$139K ﹤0.01% 900
2023
Q1 		$876K Sell
1,828
-661
-27% -$309K ﹤0.01% 887
2022
Q4 		$1.05M Sell
2,489
-1,443
-37% -$582K ﹤0.01% 778
2022
Q3 		$1.64M Buy
3,932
+2,005
+104% +$1,000K ﹤0.01% 735
2022
Q2 		$954K Sell
1,927
-3,569
-65% -$1.86M ﹤0.01% 845
2022
Q1 		$3.1M Buy
5,496
+144
+3% +$86.8K ﹤0.01% 673
2021
Q4 		$4.04M Buy
5,352
+166
+3% +$124K 0.01% 624
2021
Q3 		$3.87M Buy
5,186
+3,585
+224% +$2.69M 0.01% 627
2021
Q2 		$1.03M Buy
1,601
+449
+39% +$273K ﹤0.01% 863
2021
Q1 		$658K Sell
1,152
-1,913
-62% -$1.13M ﹤0.01% 879
2020
Q4 		$1.79M Sell
3,065
-1,020
-25% -$581K ﹤0.01% 624
2020
Q3 		$2.11M Buy
4,085
+343
+9% +$174K 0.01% 548
2020
Q2 		$1.69M Buy
3,742
+1,353
+57% +$597K ﹤0.01% 589
2020
Q1 		$837K Buy
+2,389
New +$878K ﹤0.01% 681
2019
Q4 		– Sell
-617
Closed -$205K – 1081
2019
Q3 		$205K Buy
+617
New +$201K ﹤0.01% 955
2013
Q3 		– Sell
-9,800
Closed -$1.1M – 617
2013
Q2 		$1.1M Buy
+9,800
New +$1.15M 0.01% 476

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Mackenzie Financial's BIO Position: Q3 2025 in Review

Mackenzie Financial sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 1,402 shares — an estimated $338K sold.

Mackenzie Financial first reported a position in BIO in Q2 2013 and held it in 23 quarters. The position peaked at $4.04M in Q4 2021. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

  • Mackenzie Financial reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
  • Mackenzie Financial sold 1,402 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $338K.
  • Mackenzie Financial first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 23 quarters.
  • Mackenzie Financial's Bio-Rad Laboratories Class A position peaked at $4.04M in Q4 2021.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Mackenzie Financial's 13F filing for Q3 2025, filed 13 Nov 2025.